Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PRNewsWire · Oct 1, 2026
Reviewing Alpha Cognition (NASDAQ:ACOG) & Karyopharm Therapeutics (NASDAQ:KPTI)Defense World · Sep 30, 2026
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRNewsWire · Sep 1, 2026
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with MyelofibrosisGuruFocus · Aug 31, 2026
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with MyelofibrosisPRNewsWire · Aug 31, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTIPRNewsWire · Aug 27, 2026Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$1.37 | -$2.32 | Miss |
| May 14, 2026 | -$1.45 | -$1.24 | Beat |
| Feb 12, 2026 | -$2.26 | -$5.68 | Miss |
| Nov 3, 2025 | -$3.47 | -$3.82 | Miss |
| Aug 11, 2025 | -$3.80 | -$4.32 | Miss |
| May 12, 2025 | -$4.21 | -$2.77 | Beat |